NeuroSense Therapeutics Ltd — Cash Flow (NASDAQ:NRSN)

Financials

Cash from operating activities 1.54 M7.59 M8.45 M-10.13 M-7.67 M — Cash from investing activities 17 K3.54 M3.65 M1 000-8 000 — Cash from financing activities 11.9 M3.69 M3.9 M10.91 M4.43 M — Free cash flow 1.54 M7.59 M8.45 M-10.14 M-7.68 M —

뉴스

로스/MKM, ALS 치료제 잠재력에 뉴로센스 주식 ’매수’ 개시

Roth/MKM initiates NeuroSense stock with buy on ALS drug potential

뉴로센스 테라퓨틱스, PrimeC 호주 특허 확보 후 주가 상승

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

신경퇴행성 치료제 개발, 뉴로센스 주가 상승세

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)